A new class of drugs, Lu-PSMA-617, track down i prostate cancers resistant achieving good success and extending the life of patients.
This was declared by an international team of researchers including Professor Johann de Bono, Professor of Experimental Cancer Medicine at the Institute of Cancer Research, London, and Medical Oncologist Advisor at the Royal Marsden NHS Foundation Trust, and Professor Ken Herrmann, Director of the Nuclear Medicine Clinic at the University Hospital from Essen, Germany.
Read Also
- Biden asks to redouble efforts to find out the origin of covid-19 | Video May 27, 2021
- Ignacio López Tarso left the hospital after being hospitalized for pneumonia Jun 4, 2022
- Named the perfect food for late dinner Jul 15, 2020
- Ucb: “So we rethought the work after the pandemic” Jul 14, 2021
- What is ‘black fungus’ affecting covid-19 patients in India? May 31, 2021
- Cases of monkeypox rise to 39 in Portugal May 24, 2022
- Gabbrielli (Iss): “Telemedicine? ‘For now it’s taking its first steps” Jul 24, 2021